Sign In
Buy LIFE
$16.89
-0.375 (-2.17%)
At Close: Jun 03, 2026
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Friday, 12'th Aug 2022 GlobeNewswire Inc.
SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRN
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
12:03pm, Thursday, 11'th Aug 2022 GlobeNewswire Inc.
Company is investigating efzofitimod in global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis patients Company is investigating efzofitimod in global pivotal Phase 3 EFZO-FIT™ study in p
Best Penny Stocks to Buy Now According To 3 Top Analysts
03:59pm, Thursday, 21'st Jul 2022 PennyStocks
Analysts say these are penny stocks to buy, do you agree?
The post Best Penny Stocks to Buy Now According To 3 Top Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt
Snap to $25? Plus This Analyst Cuts Price Target On Amazon.com
12:43pm, Thursday, 21'st Jul 2022 Benzinga
Keybanc cut the price target for Snap Inc. (NYSE: SNAP) from $27 to $25. Snap is scheduled to release its second-quarter results after the closing bell on Thursday. Snap shares rose 0.3% to $15.55 i
$1.4 Million Bet On This Healthcare Stock? 4 Penny Stocks Insiders are Buying
12:16pm, Thursday, 07'th Jul 2022 Benzinga
U.S. stock futures traded higher this morning on Thursday after closing slightly higher on Wednesday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell share
aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment
12:00pm, Tuesday, 14'th Jun 2022 GlobeNewswire Inc.
Poster to be presented at the Keystone Symposia on Tissue Fibrosis and Repair.
aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference
08:00am, Monday, 13'th Jun 2022
Conference hosted by The Ohio State University's Center for RNA Biology to showcase latest advancements in tRNA biology Conference hosted by The Ohio State University's Center for RNA Biology to showc
aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference
08:00am, Wednesday, 01'st Jun 2022
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA synt
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00pm, Friday, 13'th May 2022 GlobeNewswire Inc.
SAN DIEGO, May 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tR
aTyr Pharma, Inc. (LIFE) CEO Dr. Sanjay S. Shukla on Q1 2022 Results - Earnings Call Transcript
09:15pm, Monday, 09'th May 2022
aTyr Pharma, Inc. (NASDAQ:LIFE ) Q1 2022 Earnings Conference Call May 9, 2022 5:00 PM ET Company Participants Dr. Sanjay S. Shukla – President and Chief Executive Officer Jill Broadfoot – Chief Fi
Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates
09:15pm, Monday, 09'th May 2022 Zacks Investment Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -29.41% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates
06:49pm, Monday, 09'th May 2022
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -29.41% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
aTyr Pharma (LIFE) Up on Orphan Drug Status for Efzofitimod
04:14pm, Thursday, 14'th Apr 2022 Zacks Investment Research
The FDA bestows an Orphan Drug status to aTyr Pharma's (LIFE) lead candidate, efzofitimod, for the treatment of systemic sclerosis. Shares rise.
aTyr Pharma (LIFE) Up on Orphan Drug Status for Efzofitimod
01:33pm, Thursday, 14'th Apr 2022
The FDA bestows an Orphan Drug status to aTyr Pharma's (LIFE) lead candidate, efzofitimod, for the treatment of systemic sclerosis. Shares rise.
aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis
12:00pm, Wednesday, 13'th Apr 2022 GlobeNewswire Inc.
Second U.S. orphan drug designation for efzofitimod clinical program Second U.S. orphan drug designation for efzofitimod clinical program
